Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Publication | Open Access

DOI Full Paper Access

168

Citations

References

2020

Year

Tim Harrison, Pascal Chanez, Francesco Menzella, Giorgio Walter Canonica, Renaud Louis, Borja G. Cosío, Njira Lugogo, Arjun Mohan, Annie Burden, Lawrence McDermott,

The Lancet Respiratory Medicine

AsthmaSevere Eosinophilic AsthmaAllergyInflammatory Lung DiseaseAllergy MedicineClinical TrialsPulmonary MedicineNasal Polyposis SymptomsEosinophilic DisorderAllergic RhinitisMedicinePulmonary DiseasePhase 3B